Israel's new biotech center aims to turn lab discoveries into drug companies — and raise $500 million to do it

Israel's universities and hospitals have produced world-class biomedical research for years, but the expensive stretch between an academic discovery and an investable drug program remains a recurring bottleneck. A new nonprofit initiative, the Israel National Biotech Innovation Center, or INBI, is designed specifically around that gap.

The center launched with 15 Israeli universities, medical centers and health organizations. The group includes major research universities as well as Clalit and Maccabi and leading hospitals. The unusual part is not simply the size of the coalition: the partners are attempting to create shared translational infrastructure for discoveries that might otherwise remain in individual laboratories or technology-transfer portfolios.

INBI's leaders say the center is in the process of raising $500 million from philanthropic sources in Israel and abroad for a 10-year program. That wording matters. The $500 million is a fundraising objective, not a completed financing round. Reporting that the center 'raised $500 million' would overstate what has been established.

The operating plan described at launch is to select cohorts of roughly 10 early-stage biotech projects a year from the partner institutions and move the strongest toward viable therapeutic programs, companies or licensing partnerships. That may involve scientific validation, development expertise, infrastructure, industry networks and capital before a project becomes attractive to conventional biotech investors.

A founding partner, Yissum, the Hebrew University's technology-transfer company, described the center as a bridge between academic discoveries and therapeutic investment or partnering opportunities. Hadasit, the commercialization company of Hadassah, similarly described the launch as a coalition aimed at advancing biomedical discoveries into new therapies. Those institutional statements corroborate the coalition and its stated purpose; they do not establish future clinical success.

Why this matters for Israel's innovation economy is the difference between discovery and translation. Software companies can often reach a product and revenue much faster than drug developers. Therapeutics require preclinical work, manufacturing, regulatory strategy and clinical trials, all of which consume time and capital before commercial value is clear. A shared national platform could reduce some early fragmentation, but its impact will depend on project selection, fundraising, execution and whether programs actually progress into independent companies, licenses or clinical development.

What to watch next: how much of the planned capital is actually committed, the criteria used to select the first cohort, which therapeutic areas are prioritized, and the first independently measurable milestones from projects that enter the program. The launch is real; the promised pipeline still has to be built.